All Stories

  1. Longevity and mortality in cats: A single institution necropsy study of 3108 cases (1989–2019)
  2. Canine meningiomas treated with three-dimensional conformal radiation therapy require magnetic resonance imaging to avoid a geographic miss
  3. Analysis of the first-time pass rate of the American College of Veterinary Emergency and Critical Care certifying examination (2010-2015)
  4. Recent advances in veterinary radiation oncology
  5. Recent advances in veterinary radiation oncology
  6. Risk Factors for Death in Dogs Treated for Esophageal Foreign Body Obstruction: A Retrospective Cohort Study of 222 Cases (1998-2017)
  7. Factors Affecting Platelet Concentration in Platelet Concentrates from Canine Blood Donors
  8. PROSPECTIVE COMPARISON OF TUMOR STAGING USING COMPUTED TOMOGRAPHY VERSUS MAGNETIC RESONANCE IMAGING FINDINGS IN DOGS WITH NASAL NEOPLASIA: A PILOT STUDY
  9. In Memoriam - Dr. Dan Cantwell
  10. Never mind the length, feel the quality
  11. A NOVEL, REMOVABLE, CERROBEND, BEAM-BLOCKING DEVICE FOR RADIATION THERAPY OF THE CANINE HEAD AND NECK: PILOT STUDY
  12. SRS patient positioning in dogs and cats
  13. VALIDATION OF AN INDEXED RADIOTHERAPY HEAD POSITIONING DEVICE FOR USE IN DOGS AND CATS
  14. Evaluation of outcome and prognostic factors for dogs living greater than one year after diagnosis of osteosarcoma: 90 cases (1997–2008)
  15. Clear Cell Ependymoma in a Dog
  16. Results of surgical excision and evaluation of factors associated with survival time in dogs with lingual neoplasia: 97 cases (1995–2008)
  17. Cats and Chemotherapy
  18. Unilateral intraocular mastocytosis and anterior uveitis in a dog with subcutaneous mast cell tumors
  19. Melanoma
  20. Calculation of body surface area via computed tomography–guided modeling in domestic rabbits ( Oryctolagus cuniculus )
  21. Follow‐up study comparing necropsy rates and discrepancies between clinical and pathologic diagnoses at a veterinary teaching hospital: 2009 versus 1989 and 1999
  22. Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma
  23. Comparative vaccine-specific and other injectable-specific risks of injection-site sarcomas in cats
  24. Development and characterization of 5 canine B-cell lymphoma cell lines
  25. In-Vivo Biodistribution and Safety of 99mTc-LLP2A-HYNIC in Canine Non-Hodgkin Lymphoma
  26. Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells
  27. Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells
  28. A High-Resolution 15,000Rad Radiation Hybrid Panel for the Domestic Cat
  29. Affinity of the alpha4–beta1 integrin-targeting peptide LLP2A to canine lymphoma
  30. T-Cell Chronic Lymphocytic Leukemia in a Double Yellow-headed Amazon Parrot (Amazona ochrocephala oratrix)
  31. Canine malignant melanoma alpha-3 integrin binding peptides
  32. Clinical outcome in 94 cases of dermal haemangiosarcoma in dogs treated with surgical excision: 1993-2007*
  33. Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas
  34. Prospective Randomized Clinical Trial Assessing the Efficacy of Denamarin for Prevention of CCNU-Induced Hepatopathy in Tumor-Bearing Dogs
  35. Outcome in dogs with surgically resected oral fibrosarcoma (1997-2008)*
  36. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma
  37. Methodologic Approaches to Histologically Distinguishing Vaccine versus Nonvaccine-Associated Sarcomas Using Validated Time and Location Vaccination Histories in Cats
  38. REIRRADIATION OF RECURRENT CANINE NASAL TUMORS
  39. Biologic Behavior and Clinical Outcome of 25 Dogs with Canine Appendicular Chondrosarcoma Treated by Amputation: A Veterinary Society of Surgical Oncology Retrospective Study
  40. Sequential Low-Dose Rate Half-Body Irradiation and Chemotherapy for the Treatment of Canine Multicentric Lymphoma
  41. ASSESSMENT OF THE ACCURACY AND PRECISION OF A PATIENT IMMOBILIZATION DEVICE FOR RADIATION THERAPY IN CANINE HEAD AND NECK TUMORS
  42. Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy*
  43. Unilateral and Bilateral Congenital Sensorineural Deafness in Client-Owned Pure-Breed White Cats
  44. Temporal changes in characteristics of injection-site sarcomas in cats: 392 cases (1990–2006)
  45. Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines
  46. A toxicity study of low-dose rate half-body irradiation and chemotherapy in dogs with lymphoma
  47. Disseminated Lymphoma of Presumptive T-cell Origin in a Great Horned Owl (Bubo virginianus)
  48. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs
  49. A Phase II Clinical Trial of Vinorelbine in Dogs with Cutaneous Mast Cell Tumors
  50. Survival, Neurologic Response, and Prognostic Factors in Dogs with Pituitary Masses Treated with Radiation Therapy and Untreated Dogs
  51. DIAGNOSIS AND TREATMENT OF CHRONIC T-LYMPHOCYTIC LEUKEMIA IN A SPOTTED HYENA (CROCUTA CROCUTA)
  52. Evaluation of strontium Sr 90 for the treatment of superficial squamous cell carcinoma of the nasal planum in cats: 49 cases (1990–2006)
  53. RESPONSE OF NINETEEN CATS WITH NASAL LYMPHOMA TO RADIATION THERAPY AND CHEMOTHERAPY
  54. Characterization of the biological behaviour of appendicular osteosarcoma in Rottweilers and a comparison with other breeds: a review of 258 dogs
  55. Clinical Outcome of Nonnasal Chondrosarcoma in Dogs: Thirty-One Cases (1986?2003)
  56. Survival, Neurologic Response, and Prognostic Factors in Dogs with Pituitary Masses Treated with Radiation Therapy and Untreated Dogs
  57. Development of a new canine osteosarcoma cell line
  58. Recurrence Rate, Clinical Outcome, and Cellular Proliferation: Indices as Prognostic Indicators after Incomplete Surgical Excision of Cutaneous Grade II Mast Cell Tumors: 28 Dogs (1994-2002)
  59. Recurrence Rate, Clinical Outcome, and Cellular Proliferation Indices as Prognostic Indicators after Incomplete Surgical Excision of Cutaneous Grade II Mast Cell Tumors: 28 Dogs (1994–2002)
  60. Tolerance of Cutaneous or Mucosal Flaps Placed into a Radiation Therapy Field in Dogs
  61. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas
  62. The use of chemotherapy in exotic animals
  63. Current therapies in exotic animal oncology
  64. Alternating Carboplatin and Doxorubicin as Adjunctive Chemotherapy to Amputation or Limb-Sparing Surgery in the Treatment of Appendicular Osteosarcoma in Dogs
  65. Concurrence between clinical and pathologic diagnoses in a veterinary medical teaching hospital: 623 cases (1989 and 1999)
  66. Alternating Carboplatin and Doxorubicin as Adjunctive Chemotherapy to Amputation or Limb-Sparing Surgery in the Treatment of Appendicular Osteosarcoma in Dogs
  67. An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors using tetrathiomolybdate: A pilot study in a canine animal model
  68. Vaccine Site-Associated Sarcoma and Malignant Lymphoma in Cats: A Report of Six Cases (1997–2002)
  69. ACCURACY OF MAGNETIC RESONANCE IMAGING FOR ESTIMATING INTRAMEDULLARY OSTEOSARCOMA EXTENT IN PRE-OPERATIVE PLANNING OF CANINE LIMB-SALVAGE PROCEDURES
  70. Computer-assisted image analysis of neovascularization in thyroid neoplasms from dogs